Jason Marks

cell therapies

[Jason Marks @rjasonmarks]

The OpenAI Ginkgo CFPS experiment is cool. It also illustrates the reality of cloud labs. 46 Ginkgo vs 6 OpenAI authors. Automation is still a massive lift. Small digital team in the wet lab tho!

[owl @owl_posting]

Endometriosis is an incredibly interesting disease

5k words, 23 minutes reading time

covering one of the strangest conditions ive ever heard about

link: https://t.co/ZRwYT0Wrhh

very grateful to @shilpap_ for initial inspiration for this piece + reviewing it!!

[Jason Marks @rjasonmarks]

Can’t wait to see Veeva Vault AI

[Jason Marks @rjasonmarks]

Prozac modulating TME is crazy -- Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis: Cell https://t.co/qezLRXz1fI

[Jason Marks @rjasonmarks]

"Among the various approaches to in vivo CAR engineering, LNP–mRNA-based CARs have a strong chance of reaching the clinic first, leveraging the manufacturing and regulatory advancements established during the COVID-19 pandemic."
https://t.co/XeXfygmyVX

[Jason Marks @rjasonmarks]

Amazing regulatory and manufacturing timelines. Wow! Impressive execution. Somewhat reminiscent of PACT Pharma’s neoepitope TCR T cell therapy. https://t.co/1MKb0fqgew

[Miles in Transit @milesintransit1]

Over the next 24 hours, Jay and I are going to be attempting to ride EVERY TRANSIT AGENCY IN THE BAY AREA THAT USES THE CLIPPER CARD!

[Ethan Perlstein 1-to-N @eperlste]

$MIRA is a watershed moment, and just the beginning of DeSci Spring.

Starting to think there are enough degens to take on all 10,000+ rare diseases.

[Jing Liang 🇺🇦 @AppleHelix]

Finally the public-private valuation gap is being arbitraged by traditional VCs beyond Kevin Tang.

[Jason Marks @rjasonmarks]

TFs ai drug discovery targets in cancer?
https://t.co/AVxhu8JLHb

[Jason Marks @rjasonmarks]

@Caltrain 3479

[Jason Marks @rjasonmarks]

Surely you’re joking, @RickRubin! A very “unexpected conversation” considering Feynman passed away in 1988. @tetranow using AI to recreate the voice and essence of Feynman. Super cool. https://t.co/QJkFb8t0To

[Jason Marks @rjasonmarks]

Current research status of anti-cancer peptides: Mechanism of action, production, and clinical applications - ScienceDirect https://t.co/gfMMSAtcIn

[Jason Marks @rjasonmarks]

Cool. In vivo dendritic cell reprogramming for cancer immunotherapy https://t.co/oUdmzUk9MZ

[Jason Marks @rjasonmarks]

When you can't use RNAseq or ctDNA -- AI traces mysterious metastatic cancers to their source https://t.co/oa8PP3eQIx

[Caltrain @Caltrain]

One ticket One ticket
to Oppenheimer to Barbie
please please

[Jason Marks @rjasonmarks]

@Jason Suit fits real nice 🤙🏻

[Jason Marks @rjasonmarks]

Context-specific antigen presentation in vivo that will improve our understanding of tumor-immune interactions
https://t.co/Bbp1gZieZ2

[Brad Loncar @bradloncar]

Cell therapy margins are the most challenging in the industry. Some companies are likely losing money on every patient. It is not in the best interest of cancer research for a math formula rather than human judgment to penalize and possibly hold back therapies of the future.

[Jason Marks @rjasonmarks]

More important data from our work PACT Pharma. Not every patient will have highly reactive TCRs. Combined with other technologies we should be able to engineer neoTCRs to demonstrate greater specificity and cytotoxicity. Personalized therapies are real. https://t.co/2cDEHo0UNS